Hornet Therapeutics

Hornet Therapeutics is a biotechnology company headquartered in London, UK, focusing on developing treatments for EBV-driven conditions. Hornet Therapeutics provides immunometabolism and cell therapy for cancer treatment. Data published by the company in the journal *Science* shows that it has introduced a potential drug intervention for diseases caused by the Epstein-Barr virus (EBV). The study specifically identified IDO-1-driven NAD biosynthesis as a metabolic pathway exploited by EBV to meet the bioenergetic demands of newly infected B cells. Targeting this pathway with an IDO-1 inhibitor in both in vitro and in vivo animal models hindered B cell transformation and EBV-driven pathogenesis. This novel early intervention approach using IDO-1 inhibition offers a therapeutic strategy for preventing EBV-associated diseases, including lymphomas.